American Well’s (AMWL) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of American Well (NYSE:AMWL) in a research report released on Wednesday morning,Weiss Ratings reports.

Separately, Wells Fargo & Company reduced their price objective on shares of American Well from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. One analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $9.17.

American Well Trading Down 6.3%

NYSE AMWL opened at $5.81 on Wednesday. The stock has a market capitalization of $93.83 million, a price-to-earnings ratio of -0.72 and a beta of 1.26. American Well has a twelve month low of $5.79 and a twelve month high of $12.95. The stock has a 50-day moving average of $6.75 and a 200 day moving average of $7.21.

American Well (NYSE:AMWL) last announced its earnings results on Tuesday, August 5th. The company reported ($1.24) earnings per share for the quarter, topping the consensus estimate of ($1.84) by $0.60. The business had revenue of $70.90 million during the quarter, compared to the consensus estimate of $63.87 million. American Well had a negative return on equity of 41.99% and a negative net margin of 46.15%. American Well has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts predict that American Well will post -9.34 EPS for the current fiscal year.

Insider Activity at American Well

In other news, Director Deborah C. Jackson sold 4,531 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $6.56, for a total transaction of $29,723.36. Following the completion of the sale, the director owned 39,132 shares in the company, valued at $256,705.92. This trade represents a 10.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Phyllis Gotlib sold 4,959 shares of the firm’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $6.11, for a total value of $30,299.49. Following the sale, the insider directly owned 127,151 shares of the company’s stock, valued at approximately $776,892.61. This trade represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 49,383 shares of company stock valued at $331,514. 11.82% of the stock is currently owned by insiders.

Institutional Trading of American Well

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new stake in shares of American Well in the second quarter valued at $39,000. Sapient Capital LLC acquired a new stake in shares of American Well during the first quarter worth about $79,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of American Well during the second quarter worth about $89,000. Engineers Gate Manager LP acquired a new stake in shares of American Well during the second quarter worth about $101,000. Finally, JPMorgan Chase & Co. increased its stake in American Well by 16.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company’s stock worth $131,000 after buying an additional 2,081 shares during the period. Hedge funds and other institutional investors own 56.05% of the company’s stock.

American Well Company Profile

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.